Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2323-2328

  Stevens, H N E ^a,b,d   Speakman, M ^c  

^a Bio Images Research Ltd   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c Glasgow Royal Infirmary ^*  (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Gamma scintigraphy; Gastrointestinal tract; Oral Controlled Absorption System; Tamsulosin OCAS; Transit

Indexed keywords

TAMSULOSIN; TECHNETIUM 99M;

ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LABORATORY TEST; NORMAL HUMAN; PHYSICAL EXAMINATION; SCINTIGRAPHY; STOMACH EMPTYING; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; DELAYED-ACTION PREPARATIONS; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; SULFONAMIDES; TABLETS; TECHNETIUM;

EID: 33748874114     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154051     Document Type: Article

References (17)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47
3. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8
4. Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883-98
5. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61
6. Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS). Eur Urol Suppl 2005;4:15-24
7. Sako K, Nakashima H, Sawada T, Fukui M. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Pharm Res 1996;13:594-8
8. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002;62:135-67
9. Michel MC, Korstanje C, Krauwinkel W, et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005;4:53-60
10. Fix JA, Sako K, Sawada T. Controlled-release oral delivery systems. In Park K, Mrsny RJ eds., Controlled drug delivery: designed technologies for the future, Chapt 2. Oxford: Oxford University Press, 2000;14-24
11. Chapple CR, Lorenz J, Mortensen R, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study. Eur Urol Suppl 2005;4:25-32
12. Chapple CR, Al-Shukri SH, Gattegno B, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Suppl 2005;4:33-44
13. Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005;4:61-8
14. Wilding I. Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy? J Clin Pharmacol 2002;42:1200-10
15. Wilding IR, Behrens C, Tardif SJ, et al. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 2003;17:1153-62
16. 1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl 2005;4:45-52
17. Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin Oral Controlled Absorption System (OCAS) and alfuzosin prolonged release (XL). Eur Urol 2006;49:501-9